{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:29:11Z","timestamp":1792009751074,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1124\/mol.111.076687","type":"journal-article","created":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T23:10:57Z","timestamp":1336086657000},"page":"199-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["The Synaptic Vesicle Glycoprotein 2A Ligand Levetiracetam Inhibits Presynaptic Ca2+ Channels through an Intracellular Pathway"],"prefix":"10.1016","volume":"82","author":[{"given":"Christian","family":"Vogl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiko","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Whalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.111.076687_bib1","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1523\/JNEUROSCI.14-09-05223.1994","article-title":"Differential expression of synaptic vesicle protein 2 (SV2) isoforms","volume":"14","author":"Bajjalieh","year":"1994","journal-title":"J Neurosci"},{"key":"10.1124\/mol.111.076687_bib2","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1126\/science.1519064","article-title":"SV2, a brain synaptic vesicle protein homologous to bacterial transporters","volume":"257","author":"Bajjalieh","year":"1992","journal-title":"Science"},{"key":"10.1124\/mol.111.076687_bib3","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1113\/jphysiol.2010.204735","article-title":"Inhibition of synaptic transmission and G protein modulation by synthetic CaV2.2 Ca2+ channel peptides","volume":"589","author":"Bucci","year":"2011","journal-title":"J Physiol"},{"key":"10.1124\/mol.111.076687_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1523\/JNEUROSCI.4521-08.2009","article-title":"SV2 renders primed synaptic vesicles competent for Ca2+-induced exocytosis","volume":"29","author":"Chang","year":"2009","journal-title":"J Neurosci"},{"key":"10.1124\/mol.111.076687_bib5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/01.STR.0000217303.22856.38","article-title":"Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia","volume":"37","author":"Costa","year":"2006","journal-title":"Stroke"},{"key":"10.1124\/mol.111.076687_bib6","doi-asserted-by":"crossref","first-page":"15268","DOI":"10.1073\/pnas.96.26.15268","article-title":"Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)","volume":"96","author":"Crowder","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.111.076687_bib7","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1523\/JNEUROSCI.2699-05.2006","article-title":"Synaptic vesicle protein 2 enhances release probability at quiescent synapses","volume":"26","author":"Custer","year":"2006","journal-title":"J Neurosci"},{"key":"10.1124\/mol.111.076687_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1113\/jphysiol.1996.sp021599","article-title":"Sources of Ca2+ for different Ca2+-activated K+ conductances in neurones of the rat superior cervical ganglion","volume":"495","author":"Davies","year":"1996","journal-title":"J Physiol"},{"key":"10.1124\/mol.111.076687_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1527-3458.2007.00005.x","article-title":"Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug","volume":"13","author":"De Smedt","year":"2007","journal-title":"CNS Drug Rev"},{"key":"10.1124\/mol.111.076687_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1527-3458.2007.00004.x","article-title":"Levetiracetam: the profile of a novel anticonvulsant drug\u2013part I: preclinical data","volume":"13","author":"De Smedt","year":"2007","journal-title":"CNS Drug Rev"},{"key":"10.1124\/mol.111.076687_bib11","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1091\/mbc.e08-07-0765","article-title":"Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons","volume":"19","author":"Dong","year":"2008","journal-title":"Mol Biol Cell"},{"key":"10.1124\/mol.111.076687_bib12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"key":"10.1124\/mol.111.076687_bib13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0092-8674(92)90319-8","article-title":"The synaptic vesicle protein SV2 is a novel type of transmembrane transporter","volume":"70","author":"Feany","year":"1992","journal-title":"Cell"},{"key":"10.1124\/mol.111.076687_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2006.02.022","article-title":"Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein","volume":"536","author":"Gillard","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/mol.111.076687_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/mol.111.076687_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2003.08.032","article-title":"Binding characteristics of [3H]UCB 30889 to levetiracetam binding sites in rat brain","volume":"478","author":"Gillard","year":"2003","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 9","key":"10.1124\/mol.111.076687_bib17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1528-1167.2005.00329.x","article-title":"Levetiracetam in the treatment of idiopathic generalized epilepsies","volume":"46","author":"Gr\u00fcnewald","year":"2005","journal-title":"Epilepsia"},{"key":"10.1124\/mol.111.076687_bib18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0896-6273(00)81046-6","article-title":"SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release","volume":"24","author":"Janz","year":"1999","journal-title":"Neuron"},{"key":"10.1124\/mol.111.076687_bib19","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1528-1167.2009.02089.x","article-title":"Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam","volume":"50","author":"Kaminski","year":"2009","journal-title":"Epilepsia"},{"key":"10.1124\/mol.111.076687_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/jm030913e","article-title":"Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity","volume":"47","author":"Kenda","year":"2004","journal-title":"J Med Chem"},{"key":"10.1124\/mol.111.076687_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","article-title":"Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy","volume":"353","author":"Klitgaard","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/mol.111.076687_bib22","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/j.1476-5381.2009.00463.x","article-title":"Levetiracetam inhibits glutamate transmission through presynaptic P\/Q-type calcium channels on the granule cells of the dentate gyrus","volume":"158","author":"Lee","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/mol.111.076687_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","article-title":"Selective blockade of N-type calcium channels by levetiracetam","volume":"43","author":"Lukyanetz","year":"2002","journal-title":"Epilepsia"},{"key":"10.1124\/mol.111.076687_bib24","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.111.076687_bib25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0028-3908(03)00248-X","article-title":"Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?","volume":"45","author":"Madeja","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1124\/mol.111.076687_bib26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1528-1167.2008.01915.x","article-title":"Seletracetam (UCB 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro","volume":"50","author":"Martella","year":"2009","journal-title":"Epilepsia"},{"key":"10.1124\/mol.111.076687_bib27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1468-2982.2008.01682.x","article-title":"Antiepileptic drugs on calcium currents recorded from cortical and PAG neurons: therapeutic implications for migraine","volume":"28","author":"Martella","year":"2008","journal-title":"Cephalalgia"},{"key":"10.1124\/mol.111.076687_bib28","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1152\/jn.2000.84.3.1346","article-title":"Diversity of channels involved in Ca2+ activation of K+ channels during the prolonged AHP in guinea-pig sympathetic neurons","volume":"84","author":"Mart\u00ednez-Pinna","year":"2000","journal-title":"J Neurophysiol"},{"key":"10.1124\/mol.111.076687_bib29","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/bjp.2008.198","article-title":"Anti-convulsive and anti-epileptic properties of brivaracetam (UCB 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A","volume":"154","author":"Matagne","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/mol.111.076687_bib30","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1528-1167.2008.01687.x","article-title":"Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes","volume":"49","author":"Matveeva","year":"2008","journal-title":"Epilepsia"},{"key":"10.1124\/mol.111.076687_bib31","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1152\/jn.00279.2011","article-title":"A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam","volume":"106","author":"Meehan","year":"2011","journal-title":"J Neurophysiol"},{"key":"10.1124\/mol.111.076687_bib32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0304-3940(86)90080-7","article-title":"Activation of M2 muscarinic receptors causes an alteration of action potentials by modulation of Ca entry in isolated sympathetic neurons of rabbit","volume":"72","author":"Mochida","year":"1986","journal-title":"Neurosci Lett"},{"key":"10.1124\/mol.111.076687_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0304-3940(86)90081-9","article-title":"Effects of Ca antagonists on the action potential and their relationship to the muscarinic ACh actions in isolated sympathetic neurons of rabbit","volume":"72","author":"Mochida","year":"1986","journal-title":"Neurosci Lett"},{"key":"10.1124\/mol.111.076687_bib34","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0306-4522(94)00508-3","article-title":"Impairment of syntaxin by botulinum neurotoxin C1 or antibodies inhibits acetylcholine release but not Ca2+ channel activity","volume":"65","author":"Mochida","year":"1995","journal-title":"Neuroscience"},{"key":"10.1124\/mol.111.076687_bib35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0896-6273(00)80209-3","article-title":"Inhibition of neurotransmission by peptides containing the synaptic protein interaction site of N-type Ca2+ channels","volume":"17","author":"Mochida","year":"1996","journal-title":"Neuron"},{"key":"10.1124\/mol.111.076687_bib36","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1073\/pnas.262787299","article-title":"Subtype-selective reconstitution of synaptic transmission in sympathetic ganglion neurons by expression of exogenous calcium channels","volume":"100","author":"Mochida","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.111.076687_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(01)01884-5","article-title":"Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slices","volume":"306","author":"Niespodziany","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1124\/mol.111.076687_bib38","doi-asserted-by":"crossref","first-page":"e29560","DOI":"10.1371\/journal.pone.0029560","article-title":"Levetiracetam reverses synaptic deficits produced by overexpression of SV2A","volume":"6","author":"Nowack","year":"2011","journal-title":"PLoS One"},{"key":"10.1124\/mol.111.076687_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1124\/mol.111.076687_bib40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.0013-9580.2004.02204.x","article-title":"Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine","volume":"45","author":"Pisani","year":"2004","journal-title":"Epilepsia"},{"key":"10.1124\/mol.111.076687_bib41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/0883073811417183","article-title":"A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures","volume":"27","author":"Schiemann-Delgado","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1124\/mol.111.076687_bib42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1113\/jphysiol.2004.080192","article-title":"G protein \u03b2\u03b3 subunits mediate presynaptic inhibition of transmitter release from rat superior cervical ganglion neurones in culture","volume":"563","author":"Stephens","year":"2005","journal-title":"J Physiol"},{"key":"10.1124\/mol.111.076687_bib43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1469-7793.2000.t01-1-00377.x","article-title":"The \u03b11B Ca2+ channel amino terminus contributes determinants for \u03b2 subunit-mediated voltage-dependent inactivation properties","volume":"525","author":"Stephens","year":"2000","journal-title":"J Physiol"},{"key":"10.1124\/mol.111.076687_bib44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756285608094212","article-title":"Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited","volume":"1","author":"Surges","year":"2008","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1124\/mol.111.076687_bib45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1528-1167.2008.01727.x","article-title":"Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy","volume":"50","author":"van Vliet","year":"2009","journal-title":"Epilepsia"},{"key":"10.1124\/mol.111.076687_bib46","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/35087000","article-title":"SV2 modulates the size of the readily releasable pool of secretory vesicles","volume":"3","author":"Xu","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1124\/mol.111.076687_bib47","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.seizure.2009.07.004","article-title":"Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission","volume":"18","author":"Yang","year":"2009","journal-title":"Seizure"},{"key":"10.1124\/mol.111.076687_bib48","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/j.1528-1167.2006.01132.x","article-title":"Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission","volume":"48","author":"Yang","year":"2007","journal-title":"Epilepsia"},{"key":"10.1124\/mol.111.076687_bib49","doi-asserted-by":"crossref","first-page":"e1001207","DOI":"10.1371\/journal.ppat.1001207","article-title":"SV2 mediates entry of tetanus neurotoxin into central neurons","volume":"6","author":"Yeh","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1124\/mol.111.076687_bib50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1053\/seiz.2000.0504","article-title":"Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents","volume":"10","author":"Zona","year":"2001","journal-title":"Seizure"},{"key":"10.1124\/mol.111.076687_bib51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.eplepsyres.2009.09.024","article-title":"Brivaracetam (UCB 34714) inhibits Na+ current in rat cortical neurons in culture","volume":"88","author":"Zona","year":"2010","journal-title":"Epilepsy Res"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24034886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24034886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.111.076687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:50:33Z","timestamp":1739944233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24034886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0026895X24034886"],"URL":"https:\/\/doi.org\/10.1124\/mol.111.076687","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Synaptic Vesicle Glycoprotein 2A Ligand Levetiracetam Inhibits Presynaptic Ca2+ Channels through an Intracellular Pathway","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.111.076687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}